%0 Journal Article
%A Beck, Michael
%A Blumenberg, Viktoria
%A Bücklein, Veit L
%A Bundschuh, Ralph A
%A Harrer, Dennis C
%A Hirschbühl, Klaus
%A Jung, Johannes
%A Kunz, Wolfgang G
%A Menhart, Karin
%A Winkelmann, Michael
%A Yakushev, Igor
%A Illert, Anna Lena
%A Eckstein, Markus
%A Völkl, Simon
%A Claus, Rainer
%A Hansmann, Leo
%A Hecker, Judith S
%A Kuwert, Torsten
%A Mackensen, Andreas
%A Subklewe, Marion
%A Hellwig, Dirk
%A Müller, Fabian
%T Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphoma.
%J EJNMMI Research
%V 15
%N 1
%@ 2191-219X
%C Heidelberg
%I Springer
%M DKFZ-2025-00672
%P 25
%D 2025
%X Despite revolutionary efficacy of CD19-CAR-T cell therapy (CAR-T) in aggressive B cell lymphoma, many patients still relapse mostly early. In early failure, distinct drugs support CAR-T which makes reliable and early prediction of imminent relapse/refractoriness critical. A complete metabolic remission (CR) on Fluor-18-Deoxyglucose (FDG) Positron-Emission-Computed Tomography (PET) 30 days after CAR-T (PET30) strongly predicts progression-free survival (PFS), but still fails in a relevant proportion of patients. We aimed to identify additional routine parameters in PET evaluation to enhance CAR-T response prediction.Thirty patients with aggressive B cell lymphoma treated with CAR-T were retrospectively analyzed. Pre-CAR-T, LDH was the strongest PFS-predictor also by multivariate analysis. Post-CAR-T, 10 out of 14 patients (71.4
%K CAR T cell therapy (Other)
%K DLBCL (Other)
%K FDG PET (Other)
%K Liver-SUV (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40095158
%2 pmc:PMC11914545
%R 10.1186/s13550-025-01201-1
%U https://inrepo02.dkfz.de/record/300195